Dallas-based biopharma company Instil Bio Inc. has appointed Jamie Freedman, M.D., PhD., as chief medical officer, bringing with him extensive experience in oncology drug development and other therapeutic areas.
Instil said that Freedman has a track record of leading programs through all phases of development, regulatory approval, and commercialization.
Founded in 2018, Instil Bio is a clinical-stage biopharmaceutical company focused on developing a pipeline of novel therapies. Its lead asset, AXN-2510, is a novel and differentiated PD-L1xVEGF bispecific antibody in development for the treatment of multiple solid tumor cancers.
“Jamie’s extensive experience and leadership in biopharmaceutical R&D will be a tremendous asset in advancing AXN-2510,” Instil CEO Bronson Crouch said in a statement.
“AXN-2510 has the potential to redefine the standard of care for solid tumors,” Freedman said. “Our opportunity to accelerate the development of this promising PD-L1xVEGF bispecific is unique, and I’m excited to join an accomplished team to advance this program with scientific rigor and clinical urgency.”
Freedman is a hematologist-oncologist and veteran biopharmaceutical executive with over 20 years of leadership experience in biopharma drug development, Instil said.
He has held executive roles at leading pharmaceutical companies including Genentech, AstraZeneca, GSK, and Merck in clinical development, in medical affairs, as oncology business head, and as country-level general manager.
Freedman’s career has led to 15 drug approvals and successful launches across multiple therapeutic areas, the company said.
Don’t miss what’s next. Subscribe to Dallas Innovates.
Track Dallas-Fort Worth’s business and innovation landscape with our curated news in your inbox Tuesday-Thursday.
R E A D N E X T
-
Fort Worth-based marketing agency The Starr Conspiracy has officially rebranded as TSC, signaling a new era with fresh leadership. CEO Ashley Bernard is steering the agency toward innovation, AI investment, and cutting-edge marketing strategies, with the rebrand unveiled at the 2024 HR Technology Conference & Exposition.
-
Trinity Christian Academy has named Lisa Wong, a former Raytheon engineer and TCA’s director of technology, as its first chief innovation officer. Wong will lead the integration of cutting-edge technology, foster innovation, and prepare students for future careers.
-
The company said that COO Jim Breuer will drive a more holistic view of its markets, strengths, and needs in project delivery and talent allocation. Kevin Hammonds succeeds John Reynolds, who will retire from the company after nearly 40 years of service.
-
Eric Matthews will provide strategic leadership to biopharma business development, and through his executive leadership, support Caris' expanding portfolio of biopharma partnerships, the company said.
-
Glenn Hamilton, MD—who held the role of chief medical officer at the San Antonio Air Logistics Center during Desert Storm—will oversee all aspects of population health, utilization management, and clinical policy at Evry Health, the Dallas-based company said.
